Aarti Drugs Limited Overview
Pro stress-test →Aarti Drugs Limited is a leading global manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals, established in 1984. The company operates as part of the $900 million Aarti Group and exports to over 100 countries, serving critical therapeutic markets including antibiotics, anti-diabetics, and anti-inflammatories.
Strategic Profile
Pro stress-test →Aarti Drugs holds market leadership in 50+ API molecules and is the world's largest manufacturer of key products like Fluoroquinolones, Tinidazole, and Metronidazole Benzoate. The company operates with GMP-certified manufacturing units and pursues vertical integration through its wholly-owned subsidiary Pinnacle Life Science, which focuses on formulation development to capture higher margins in the pharmaceutical value chain.
Competitive Landscape
Pro stress-test →Aarti Drugs competes in the fragmented Indian API market against peers like Divi's Laboratories, Laurus Labs, and Neuland Pharma. Indian API manufacturers are gaining global market share as customers diversify away from China-dependent supply chains. Divi's Labs achieved 19.3% revenue growth in FY25, while Laurus and Neuland posted strong profitability growth, creating competitive pressure despite Aarti's established market position in specific molecules.
Industry Context
Aarti Drugs Limited operates in Pharmaceutical Active Ingredients (APIs) & Specialty Chemicals.
Key facts
Founded: 1984 · Headquarters: Mumbai, India · Revenue: ₹2,403 Cr (~$287M) FY2025-26 · Market cap: ₹3,358-3,511 Cr (~$400-420M)